Adam Sperling
Medical Oncology · Boston, MANPI 1023303161
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (47.4%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. F. Hoffmann-la Roche AG accounts for 60.8% of it on its own, with 2 other manufacturers making up the rest. Reporting peaked in 2022 at $1,824 and has fallen 90.5% since, to $174 in 2024. That places this record below the midpoint for medical oncology clinicians in MA, where the typical reported total is $2,567.
Across 5 payments — averaging $599.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- F. Hoffmann-la Roche AG$2K
- Adaptive Biotechnologies Corporation$1K
- E.r. Squibb & Sons, L.L.C.$174
Across 23 payments — averaging $179,558 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$4.1M
- Bristol Myers Squibb$11K
What the payments were for
- Consulting fees$1,00033%
- Travel & lodging$1,42047%
- Food & beverage$57819%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| F. Hoffmann-la Roche AG | 3 | $1,824 |
| Adaptive Biotechnologies Corporation | 1 | $1,000 |
| E.r. Squibb & Sons, L.L.C. | 1 | $174 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,997 in reported general payments places this provider in the 50th percentile of 308 medical oncology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 16 | $270,684 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Boston
- George DemetriBoston$1.6M
- Keith FlahertyBoston$932K
- Alicia MorgansBoston$690K
- Pasi Antero JanneBoston$458K
- Robert HaddadBoston$451K
- Irene GhobrialBoston$431K
- Joaquin Bellmunt MolinsBoston$415K
- Jeremy AbramsonBoston$334K
- Justin GainorBoston$324K
- Narjust FlorezBoston$324K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.